S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Entera Bio Stock Forecast, Price & News

+0.01 (+0.62%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
45,648 shs
Average Volume
32,014 shs
Market Capitalization
$38.39 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Stock Forecast (MarketRank)

Overall MarketRank

1.58 out of 5 stars

Medical Sector

978th out of 1,411 stocks

Biological Products, Except Diagnostic Industry

149th out of 215 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
Entera Bio logo

About Entera Bio (NASDAQ:ENTX)

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

ENTX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
$-12.19 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$570 thousand
Book Value
$0.95 per share


Free Float
Market Cap
$38.39 million
Not Optionable

Entera Bio Frequently Asked Questions

Should I buy or sell Entera Bio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Entera Bio stock.
View analyst ratings for Entera Bio
or view top-rated stocks.

What is Entera Bio's stock price forecast for 2022?

2 Wall Street research analysts have issued 12 month price targets for Entera Bio's shares. Their ENTX stock forecasts range from $6.00 to $12.00. On average, they anticipate Entera Bio's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 455.6% from the stock's current price.
View analysts' price targets for Entera Bio
or view top-rated stocks among Wall Street analysts.

How has Entera Bio's stock performed in 2022?

Entera Bio's stock was trading at $2.8150 at the start of the year. Since then, ENTX shares have decreased by 42.5% and is now trading at $1.62.
View the best growth stocks for 2022 here

When is Entera Bio's next earnings date?

Entera Bio is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Entera Bio

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) posted its quarterly earnings results on Thursday, May, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.05. Entera Bio had a negative trailing twelve-month return on equity of 27.70% and a negative net margin of 1,345.02%. During the same period in the prior year, the business posted ($0.43) EPS.
View Entera Bio's earnings history

Who are Entera Bio's key executives?

Entera Bio's management team includes the following people:
  • Dr. Spiros Jamas Sc.D., Chief Exec. Officer (Age 61, Pay $392k)
  • Ms. Miranda J. Toledano M.B.A., Chief Bus. Officer, CFO, Head of Corp. Strategy & Independent Director (Age 45, Pay $65.2k)
  • Dr. Hillel Galitzer, Chief Operating Officer (Age 44, Pay $380k)
  • Dr. Phillip Schwartz Ph.D., Exec. VP, Pres of R&D and Director (Age 60, Pay $502k)
  • Dr. Arthur C. Santora II, M.D., Ph.D., Chief Medical Officer (Age 71)

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include (CGC), Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

When did Entera Bio IPO?

(ENTX) raised $11 million in an IPO on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

Who are Entera Bio's major shareholders?

Entera Bio's stock is owned by many different institutional and retail investors. Top institutional investors include PNC Financial Services Group Inc. (0.04%). Company insiders that own Entera Bio stock include Ramesh Ratan, Ron Mayron and Yonatan Malca.
View institutional ownership trends for Entera Bio

Which institutional investors are buying Entera Bio stock?

ENTX stock was bought by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc.. Company insiders that have bought Entera Bio stock in the last two years include Ramesh Ratan, Ron Mayron, and Yonatan Malca.
View insider buying and selling activity for Entera Bio
or or view top insider-buying stocks.

How do I buy shares of Entera Bio?

Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $1.62.

How much money does Entera Bio make?

Entera Bio (NASDAQ:ENTX) has a market capitalization of $38.39 million and generates $570 thousand in revenue each year. The company earns $-12.19 million in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does Entera Bio have?

Entera Bio employs 18 workers across the globe.

How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for Entera Bio is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at [email protected].

This page (NASDAQ:ENTX) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.